OTTAWA, Oct. 14, 2016 /CNW/ - Hesira Med Inc. is pleased to announce that OSSIX™ GRAFT an allograft bone particulate is now commercially available for use in Canada. It is part of the OSSIX® line of dental regenerative products which is known to provide proven results to facilitate quality bone. OSSIX™ GRAFT is applicable for socket preservation, ridge augmentation and regeneration of defects. Allowash® technology is used to retain the structural integrity of the bone. It is osteoinductive and supports fibroblast penetration, as well as tissue remodeling.
"We are passionate about importing products into Canada that have previously not been available. We believe that Canadian clinicians deserve best-in-class dental regenerative materials in order to achieve ideal treatment outcomes for patients." - Chris Carriere, Managing Director.
About Hesira Med Inc.
Hesira Med is a Canadian owned and operated medical device distribution company. HesiraMed.com
LinkedIn: Hesira Med Inc
Facebook: Hesira Med
SOURCE Hesira Med Inc
Image with caption: "Logo: Hesira Med (CNW Group/Hesira Med Inc)". Image available at: https://photos.newswire.ca/images/download/20161014_C2666_PHOTO_EN_795685.jpg
For further information: Chris Carriere, email@example.com, 1-844-HESIRA-1